Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MNKD-201 in Idiopathic Pulmonary Fibrosis
NCT07344558Phase 1Completed
- Sponsor
- MannKind
- Start
- Dec 2025
- Primary completion
- Jun 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of nintedanib dry powder inhaler in idiopathic pulmonary fibrosis (IPF) (3 arms), sponsored by MannKind. Primary endpoints: Events of Bronchospasm, Changes in FEV1 from pre-dose to post-dose and 6 more. Started Dec 2025; status: completed.
02
Drugs
nintedanib dry powder inhaler
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT07344558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07344558.